91成人短视频

Process intensification, recycling innovations, and increased industry collaboration will significantly improve biomanufacturing sustainability and reduce its environmental impact.

The healthcare industry, including therapeutic drug manufacturing, accounts for approximately 4鈥�5% of global greenhouse gas (GHG) emissions (1). Consequently, drug manufacturers, investors, and regulatory bodies are under mounting pressure to reduce the industry鈥檚 GHG emissions and plastic waste streams.

Reducing emissions necessitates the optimization of manufacturing processes and the responsible sourcing of energy, water, and raw materials. Thus far, transitioning from stainless steel systems to single-use technologies (SUTs) has increased the environmental sustainability of bioprocesses. This is mainly due to a reduction in facility footprints, energy consumption, and water usage (2). Furthermore, process intensification has increased the efficiency and selectivity of biomanufacturing, resulting in lower resource usage and higher throughput. Applying circularity principles to materials such as plastics can also play a key part in waste reduction, but it remains in its infancy. In addition, the ecological footprint of technology providers is interconnected to the final therapeutic product.

This article focuses on current efforts to reduce bioprocess environmental impacts via process intensification and the reduction of material footprints, with the production of monoclonal antibodies (mAbs) serving as the primary example...